Work

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?

Year: 2012

Type: editorial

Abstract: The risk adaptive therapy approach within low risk patients may involve limiting post-transplant IMiD exposure in patients who have a higher potential for SPM development. It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up.

Source: Oncotarget

DOI: 10.18632/oncotarget.661

Author: Saad Z Usmani

Institutions: University of Arkansas Medical Center, University of Arkansas for Medical Sciences

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W1794151065

Cites: 10

Cited by: 3

Related to: 10